Biologics Safety: Stronger Pharmacovigilance For First-In-Class BLAs Urged In JAMA Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Over 23 percent of biologics were subject to post-approval “Dear Doctor” communications or black box warnings during a 12-year period, study finds.